Accessibility Menu
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics(NASDAQ) MLTX

Current Price$19.01
Market Cap$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+81%
5 Year+90%
1 Year-65%
1 Month-5%
MoonLake Immunotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 19.022026-07-24
MoonLake Immunotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.35%USD 19.682026-07-17
1 month-4.9%USD 20.002026-06-24
3 month+10.71%USD 17.182026-04-24
Year to date+44.31%USD 13.182025-12-31
1 year-65.44%USD 55.032025-07-24
3 year-66.19%USD 56.252023-07-25
5 year+90.2%USD 10.002021-07-23
Since inception+81.32%USD 10.492020-10-20

MoonLake Immunotherapeutics Financials at a Glance

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$257.08M

EPS (TTM)

-$3.87

P/E Ratio

-4.91

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$19.01

Volume

0

Open

$19.22

Previous Close

$19.01

Daily Range

$18.82 - $19.25

52-Week Range

$5.95 - $62.75

Estimated Earnings Date

Aug 4, 2026

MLTX News

SellAlert-Blue.png

MoonLake Immunotherapeutics' CFO Sells 39K Shares

Lawrence Rothman, CFAJul 3, 2026
Healthcare professional inspecting charts

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

Eric VolkmanJun 24, 2026
SellAlert-Red.png

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?

Pamela KockJun 4, 2026
SellAlert-Red.png

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

Robert IzquierdoApr 18, 2026
SellAlert-Green.png

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

Pamela KockApr 7, 2026
BuyAlert-Purple.png

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Jonathan PoncianoMar 16, 2026
SellAlert-Green.png

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash

Jonathan PoncianoNov 28, 2025
PiggyBank-BuyAlert-Purple.png

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out

Adam PalascianoNov 18, 2025
Page 1

MLTX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MoonLake Immunotherapeutics

MoonLake makes medicines for painful skin and joint diseases. These treatments help people with long-term swelling and sores. The company tests new ways to heal damaged tissue.

The Clinical Pipeline

  • Sonelokimab (SLK): core investigational therapy designed to block specific proteins that cause inflammation in the skin and joints.
  • HS Treatments: clinical program for hidradenitis suppurativa, a chronic disease causing painful lumps and sores under the skin.
  • Joint Care: research into treatments for psoriatic arthritis and other inflammatory conditions affecting the spine and limbs.
  • PPP Therapy: experimental medicine for palmoplantar pustulosis, an inflammatory condition causing blisters on hands and feet.

Strategic Growth Steps

  • Exclusively licensed Sonelokimab from Merck Healthcare KGaA in April 2021 to lead its global clinical development.
  • Partnered with SHL Medical in May 2023 to develop an autoinjector for patient self-administration.
  • Signed a manufacturing agreement with Richter BioLogics in July 2021 to produce supplies for clinical trials.
  • Obtained Fast Track designation from the U.S. Food and Drug Administration in February 2026 for its hand and foot treatment.

Why Nanobodies Matter

MoonLake uses Nanobody technology to build medicines that are much smaller than traditional treatments. This design helps the therapy reach deep into inflamed tissues where larger molecules might struggle to penetrate.

Recent Financial Performance

  • Operating income was -$65.2 million in Q4 2025, worsening by 31.5% compared to the previous year.
  • Net loss reached $62.4 million in Q4 2025, which deepened by 36.9% from the prior year period.
  • Free cash flow was -$58.8 million in Q4 2025, representing a 20.9% decline year-over-year.
  • Market capitalization reached $849.6 million in Q4 2025, down 75.1% from $3.4 billion in Q4 2024.

Bottom Line

MoonLake has evolved from a research startup into a late-stage developer focused on a single, versatile medicine. The company is now scaling its manufacturing and preparing for the potential commercial launch of its flagship therapy.

AI Generated • May 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

130

CEO

Jorge Santos da Silva, PhD

Website

www.moonlaketx.com

Headquarters

Zug, ZG 6300, CH

MLTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-85.61%

Return on Capital

-64.40%

Return on Assets

-64.21%

Earnings Yield

-20.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.62M

Volume

0

Avg. Volume

1.10M

Financials (TTM)

Gross Profit

-$2.34M

Operating Income

-$267.37M

EBITDA

-$245.81M

Operating Cash Flow

-$224.15M

Capital Expenditure

$0.00

Free Cash Flow

-$224.15M

Cash & ST Invst.

$357.92M

Total Debt

$100.80M

MoonLake Immunotherapeutics Performance Analysis

MoonLake Immunotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
MoonLake Immunotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
MoonLake Immunotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.70-75.1%
20232023-12-31USD -0.73-56.9%
20242024-12-31USD -1.89158.1%
20252025-12-31USD -3.5386.4%
MoonLake Immunotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-38.1%
Q32025-09-30-26.4%
Q42025-12-3115.5%
Q12026-03-31-5.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$845.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.09M

N/A

Employees

130

N/A

Net Income

-$69.71M

-74.5%

EBITDA

-$65.97M

-64.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$357.92M

-25.5%

Total Debt

$100.80M

+33.3%

Accounts Receivable

$5.76M

+92.9%

Inventory

$0.00

N/A

Long Term Debt

$99.88M

+34.7%

Short Term Debt

$920.00K

-35.8%

Return on Assets

-64.21%

N/A

Return on Invested Capital

-75.47%

N/A

Free Cash Flow

-$66.29M

-73.6%

Operating Cash Flow

-$66.29M

-73.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVBPArriVent BioPharma, Inc.
$31.73+0.60%
ABSIAbsci Corporation
$7.56-6.32%
MGTXMeiraGTx Holdings plc
$11.77-2.73%
OLMAOlema Pharmaceuticals, Inc.
$11.70-0.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NOKNokia
$9.10-0.06%
STAKStak
$9.27+6.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.00-0.03%

Questions About MLTX

What is the current price of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics is trading at $19.01 per share.

What is the 52-week range for MoonLake Immunotherapeutics?

Over the past 52 weeks, MoonLake Immunotherapeutics has traded between $5.95 and $62.75.

How much debt does MoonLake Immunotherapeutics have?

As of the most recent reporting period, MoonLake Immunotherapeutics reported total debt of $100.80M.

How much cash does MoonLake Immunotherapeutics have on hand?

MoonLake Immunotherapeutics reported $298.49M in cash and cash equivalents in its most recent financial results.

What is MoonLake Immunotherapeutics’s dividend yield?

MoonLake Immunotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services